



Attorney's Docket No. 8405-252

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: David Rizzieri et al.  
Serial No.: 10/008,062  
Filed: October 19, 2001  
For: **ANTI-TENASCIN MONOCLONAL ANTIBODY  
THERAPY FOR LYMPHOMA**

Date: February 26, 2002


Commissioner for Patents  
Washington, DC 20231

**INFORMATION DISCLOSURE STATEMENT  
CITATION UNDER 37 C.F.R. § 1.97**

Sir:

Attached is a list of documents on Form PTO-1449 together with a copy of each identified document. It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP.

Respectfully submitted,

  
Kenneth D. Sibley  
Registration No. 31,665

Correspondence Address:




20792

PATENT TRADEMARK OFFICE

Tel (919) 854-1400  
Fax (919) 854-1401

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on February 26, 2002.

  
Lucille H. Gillette Date of Signature: February 26, 2002

FORM PTO-1449 U.S. Department of Commerce  
Patent and Trademark Office

Attorney Docket Number 5405-252

Serial No.  
10/008,062

LIST OF DOCUMENTS CITED BY APPLICANT

(Use several sheets if necessary)



Applicants: David Rizzieri et al.

Filing Date October 19, 2001

Group

U. S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	1.	4,474,893	10/02/84	Reading	436	547	
	2.	4,676,980	06/30/87	Segal et al.	424	85	
	3.	4,816,567	03/28/89	Cabilly et al.	530	387	
	4.	5,624,659	04/29/97	Bigner et al.	424	1.49	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes   No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	5.	Aeschlimann et al., <i>Identification of Gln726 in nidogen as the amine acceptor in transglutaminase-catalyzed cross-linking of laminin-nidogen complexes</i> , J Biol Chem, 267:11316-21 (1992).
	6.	Akabani et al., <i>Dosimetry of <sup>131</sup>I-Labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors</i> , J Nucl Med., 40:631-638 (1999).
	7.	Back et al., <i>Tenascin expression in activated lymphatic cells and gastrointestinal tracts</i> , Verh Dtsch Ges Pathol (1996) 80:326 (in German) (with English abstract).
	8.	Bell WR, <i>The fibrinolytic system in neoplasia</i> , Sem Throm Hemostat., 22:459-478 (1996).
	9.	Bigner et al., <i>Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial of results</i> , J Clin Oncol, 16:2202-2212 (1998).
	10.	Birchall et al., <i>A microcomputer algorithm for solving first-order compartmental involving recycling</i> , Health Physics, 56:857-868 (1989).
	11.	Bourdon et al., <i>Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody</i> , Cancer Res, 43:2796-2805 (1983).

EXAMINER

\*EXAMINER

DATE CONSIDERED


Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce  
Patent and Trademark Office

Attorney Docket Number 5405-252

Serial No.  
10/008,062

LIST OF DOCUMENTS CITED BY APPLICANT



(Use several sheets if necessary)

Applicants: David Rizzieri et al.

Filing Date October 19, 2001

Group

12.	Broll et al., <i>Expression of tenascin in tumors of the esophagus, small intestine and colorectum</i> , Gen Diag Pathol, 141:111-119 (1995).
13.	Bullard et al., <i>In vivo imaging of intracranial human glioma xenografts comparing specific with nonspecific radiolabeled monoclonal antibodies</i> , J Neurosurg 64:257-262 (1986).
14.	Bullard et al., <i>Specific imaging of human brain tumor xenografts utilizing radiolabelled monoclonal antibodies (MAbs)</i> , Nuklearmedizin-Nuclear Med, 25:210-215 (1986).
15.	Folkman, J., <i>Anti-angiogenesis: new concept for therapy of solid tumors</i> , Ann. Surg., 175:409-416 (1972).
16.	Forsberg et al., <i>Skin wounds and severed nerves heal normally in mice lacking tenascin-C</i> , Proc Natl Acad Sci USA, 93:6594-6599 (1996).
17.	Harris et al., <i>A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group</i> , Blood:1361-1392 (1994).
18.	Harris et al., <i>Growth factors and angiogenesis in breast cancer</i> , Recent Results in Cancer Research, 127:35-41 (1993).
19.	He et al., <i>Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein Tenascin</i> , J. Neuroimmunol., 52:127-137 (1994).
20.	Hettasch et al., <i>Tissue transglutaminase expression in human breast cancer</i> , Lab. Invest., 75:637-645 (1996).
21.	Huse, M., <i>Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda</i> , Science, 246:1275-1281 (1989).
22.	Jahkola et al., <i>Expression of tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis</i> , Int J Cancer, 69:445-447 (1996).
23.	Jallo et al., <i>Tenascin-C expression in the cyst wall and fluid of human brain tumors correlates with angiogenesis</i> , Neurosurgery, 41:1052-1059 (1997).
24.	Kawakatsu et al., <i>Human carcinoma cells synthesize and secrete tenascin in vitro</i> , Jpn J Cancer Res. 83:1073-1080 (1992).
25.	Kojima et al., <i>Requirement for transglutaminase in the activation of latent transforming growth factor-beta in bovine endothelial cells</i> , J Cell Biol., 121:439-448 (1993).
26.	Kostianovsky et al., <i>Tenascin-C expression in ultrastructurally defined angiogenic and vasculogenic lesions</i> , Ultrastructural Pathol, 21:537-544 (1997).
27.	Kusagawa et al., <i>Expression and degradation of tenascin-C in human lung cancers</i> , British J Cancer, 77:98-102 (1998).
28.	Mackie EJ, <i>Molecules in focus: tenascin-C</i> , Int J Biochem Cell Biol, 29:1133-1137 (1997).
29.	Mackie et al., <i>Regulation of tenascin-C expression in Bone Cells by TGF-<math>\beta</math></i> , Bone, 22:301-307 (1998).
30.	Non-Hodgkin's Lymphoma Pathologic Classification Project, <i>National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas</i> , Cancer, 49:2112-2135 (1982).
31.	Reist et al., <i>Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent</i> , Clinical Cancer Research, 4:2495-2502 (1998).
32.	Ribatti et al., <i>Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study</i> , Eur J. Haematology, 56:45-53 (1996).

EXAMINER

\*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Attorney Docket Number 5405-252

Serial No.  
10/008,062

(Use several sheets if necessary)

Applicants: **David Rizzieri et al.**

**Filing Date** **October 19, 2001**

Group

- |     | Abstract 13, 2001   | Group |
|-----|---|-------|
| 33. | Rizzieri et al., <i>Markers of angiogenesis, factor VIII and tenascin, correlate with disease activity in patients with non-Hodgkin's lymphoma</i> , Abstract #4339, Blood 94 (Supp 1): 4339 (1999).                |       |
| 34. | Sane et al., <i>Vitronectin is a substrate for transglutaminases</i> . Biochem Biophys Res Commun., 157:115-20 (1988).  |       |
| 35. | Schold et al., <i>Distribution and dosimetry of I-123 labeled monoclonal antibody 81C6 in patients with anaplastic glioma</i> , Invest Radiol, 28:488-496 (1993).   |       |
| 36. | Soini et al., <i>Tenascin in reactive lymph nodes and in malignant lymphomas</i> , Pathol Res Pract., 188:1078-1082 (1992).   |       |
| 37. | Takvorian et al., <i>Treatment of relapsed non-Hodgkin's lymphoma utilizing purged autologous bone marrow</i> , UCLA Symposia on Molecular and cellular Biology, New Series, 27:113-120 (1985).                     |       |
| 38. | Turner et al., <i>Complexation of fibronectin with tissue transglutaminase</i> , Biochemistry, 28: 628-635 (1989).  |       |
| 39. | Upchurch et al., <i>Cellular transglutaminase has affinity for extracellular matrix</i> , In Vitro Cell Dev Biol., 23:795-800 (1987).   |       |
| 40. | Vacca et al., <i>Expression of tenascin is related to histologic malignancy and angiogenesis in B-cell non-hodgkin's lymphomas</i> , Leukemia and Lymphoma, 22:473-481 (1996).                                      |       |
| 41. | Walker et al., <i>Interaction of human IgG chimeric antibodies with the human FcRI and FcRII receptors: requirements for antibody-mediated host cell-target cell interaction</i> , Molec. Immun., 26:403-11 (1989). |       |
| 42. | Zagzag et al., <i>Tenascin-C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro</i> , Cancer Research, 56:182-189 (1996).   |       |
| 43. | Zalutsky et al., <i>A method for the radiohalogenation of proteins resulting in decreased thyroid uptake of radioiodine</i> , Appl. Radiat. Isot., 38:1051-1055 (1987).   |       |
| 44. | Zalutsky et al., <i>Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent</i> , Nucl Med Biol, 23:449-458 (1996).  |       |

EXAMINER

\*EXAMINER

DATE CONSIDERED

DATE CONSIDERED \_\_\_\_\_

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant